Assessment of the Safety of Tofacitinib Among Patients With Psoriasis: A Systematic Review and Meta-Analysis.

Cureus · 2024 · PMC11508819 · PMID 39463512

Europe PMC DOI

hedged sentence

0.4500

closest p · 9.0× alpha

0.4500

boldest claim

The sentences

did not reach statistical significanceP = 0.45not close (p > 0.1)

Similarly, the risk of SAEs was also higher in the Tofacitinib group, yet it did not reach statistical significance (OR: 1.32, 95% CI: 0.64-2.74; P = 0.45).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.